Mitotic drivers--inhibitors of the Aurora B Kinase.
In this article we review the basis for current anti-mitotic, anti-cancer, therapy and the potential for Aurora B kinase inhibitors as a new differentiated class of agents--"mitotic drivers". We review the current understanding of Aurora B inhibition from basic cell biology to inhibitors currently undergoing clinical trials.
Keen
Nicholas
N
AstraZeneca Pharmaceuticals, R&D Boston, Waltham, MA 02451, USA. nick.keen@astrazeneca.com
Taylor
Stephen
S
D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000627:therapeutic use*; D064107:Aurora Kinase B; D064127:Aurora Kinases; D002453:Cell Cycle; D004195:Disease Models, Animal; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008495:Medical Oncology / Q000379:methods / Q000639:trends; D008870:Microtubules / Q000187:drug effects; D008938:Mitosis; D008954:Models, Biological; D009369:Neoplasms / Q000378:metabolism*; D047428:Protein Kinase Inhibitors / Q000737:chemistry / Q000627:therapeutic use*; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D008941:Spindle Apparatus / Q000187:drug effects
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; C576921:AURKB protein, human; D064107:Aurora Kinase B; D064127:Aurora Kinases; D017346:Protein Serine-Threonine Kinases